The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
ASCO 2016 | MAINTAIN Trial First Results – Rituximab Versus Observation for Maintenance in Patients with MCL
This ASCO 2016 oral abstract presentation took place on Sunday June 5, 9:45am–12:45pm, during the ‘Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia’ session. This session was chaired by Pr Gilles Salles, Head of the Hematology Department in South Lyon hospitals, Lyon, France.
The abstract (#7503) was presented by Dr Mathias J Rummel, head of the Department of Hematology at the Clinic for Hematology and Medical Oncology at the Justus-Liebig University-Hospital, Gießen, Germany.
In FL, maintenance rituximab is a standard care option; however, this is not the case for MCL. A prospective, randomized, multicenter study (NCT00877214) was initiated to investigate observation compared to maintenance rituximab following induction with bendamustine-rituximab in newly diagnosed MCL patients.
Beginning in April 2009, this study’s primary outcome measure was PFS. Inclusion criteria consisted of: stage II (with bulky disease >7 cm), III, or IV disease; CD20+ lymphoma verified by histological analysis; general condition WHO 0–2; and age between 18–80 years.
Induction of up to 6 cycles of bendamustine-rituximab was administered to patients, and the 122 who responded were randomized to either 375mg/m2 rituximab every 2 months for 2 years (n=60) or observation only (n=62).
- Median age = 70 years
- Median follow-up = 58.6 months
- No significant difference was found for PFS between the 2 arms
- Median PFS: rituximab pts = 72.3 months (21 events); observation pts = 54.7 months (29 events; HR, 0.71; 95% CI, 0.41–1.23; P = 0.2267)
- No significant difference was found for OS between the 2 arms
- Median OS: rituximab pts = not reached (11 events); observation pts = not reached (15 events; HR, 1.51; 95% CI, 0.70–3.25; P = 0.2974)
Once again, the superb efficacy of bendamustine-rituximab was demonstrated in elderly patients with MCL. However, no significant difference in PFS or OS was found between the rituximab maintenance and observation arms. Therefore, it was concluded that there is no evidence to support the use of rituximab maintenance after bendamustine-rituximab in elderly MCL patients. Furthermore, the activity of bendamustine-rituximab without maintenance rituximab appeared comparable to R-CHOP plus maintenance rituximab (PFS and OS).
References